• Menu
  • Skip to right header navigation
  • Skip to primary navigation
  • Skip to content

DesignCaffeine, Inc.

Design That Works.

  • About
    • About Greg Nudelman
    • Clients
  • Speaking & Workshops
    • UX of AI Keynote/Workshop
    • Mobile Lean UX Academy
  • 4 Books
  • Articles
  • Contact
  • About
    • About Greg Nudelman
    • Clients
  • Speaking & Workshops
    • UX of AI Keynote/Workshop
    • Mobile Lean UX Academy
  • 4 Books
  • Articles
  • Contact
  • DesignOps
  • Artificial Intelligence
  • IoT & Analytics
  • Lean UX
  • Mobile
  • Search
  • Design Strategy
  • DesignOps
  • Artificial Intelligence
  • IoT & Analytics
  • Lean UX
  • Mobile
  • Search
  • Design Strategy

US Patent #6677343: Substituted Piperazine Compounds

Key Ranolazine patent for CV Therapeutics/Gilead: a novel class of compounds that are useful in the treatment of cardiovascular diseases including arrhythmias, angina, congestive heart disease, and myocardial infarction.

Jan 20th, 2010 //  by Greg Nudelman

Novel compounds of the general formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal’s (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.

Granted by the US Patent Office February 22, 2001 ⇒

Category: InventionsTag: Biochemistry, Medicinal Chemistry, Patent, Pharmaceutical

Previous Post: « US Patent #6180615: Propargyl Phenyl Ether A2A Receptor Agonists
Next Post: Information Architecture Summit * April 10-14, 2008 * Miami, FL »

Copyright © 2023 DesignCaffeine, Inc. · All Rights Reserved · Powered by Mai Theme